Abstract
Background: TB Is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2016, there were an estimated 1.3 million TB deaths among HIV negative people (down from 1.7 million in 2000) and an additional 374 000 deaths among HIV-positive people.
 Methods: This is a retrospective study conducted in the department of Pulmonary medicine. Early morning sputum sample was collected from the patients in a clean sterile container.
 Results: Among the total 500 samples, 110 were detected tuberculosis positive by CBNAAT method and 390 were negative. And among 110 positive cases, 107 were Rifampicin sensitive and 3 were Rifampicin resistant
 Conclusion: CBNAAT detects pulmonary TB with greater efficacy than sputum microscopy also helping in early diagnosis in less than 2 hours. It also detects rifampicin resistance with high specificity and can be used for screening for MDR-TB so that early therapy can be started thus decreasing the incidence of MDR-TB. WHO recommends CBNAAT for early diagnosis of pulmonary tuberculosis and detection of rifampicin resistance and retreatment cases, who are at risk of MDR-TB.
 Keywords: CBNAAT, MDR, Pulmonary tuberculosis
Highlights
TB Is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS
Morning sputum samples were tested by CBNAAT method the positive have no specific age group and irrespective of sex
Past studies on drug resistance have shown that rifampicin resistance is seldom detected alone and 90% of rifampicin resistance patients turn out to be MDR-TB, CBNAAT can be a useful test for screening for MDR-TB
Summary
TB Is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2016, there were an estimated 1.3 million TB deaths among HIV negative people (down from 1.7 million in 2000) and an additional 374 000 deaths among HIVpositive people.[1]. The TB mortality rate is falling at about 3% per year. TB incidence is falling at about 2% per year; this needs to improve to 4-5% per year by 2020 to reach the first milestones of the End TB Strategy. Sample (2 ml mucuprulent) was collected in a falcon tube. The sample was loaded into cartridge and analyzed for presence of mycobacteria and rifampicin resistance in GX4 System (with 4 modules)[3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
